Long-term maraviroc use as salvage therapy in HIV-2 infection

References 1 Obeid S, Printsevskaya SS, Olsufyeva EN et al. Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chemother 2011; 66: 1287–94. 2 Balzarini J, Keyaerts E, Vijgen L et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res 2006; 72: 20–33. 3 Preobrazhenskaya MN, Olsufyeva EN. Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry. Antiviral Res 2006; 71: 227–36. 4 Barcia-Macay M, Seral C, Mingeot-Leclercq MP et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50: 841–51. 5 Nagy PD, Pogany J. The dependence of viral RNA replication on co-opted host factors. Nat Rev Microbiol 2011; 10: 137–49. 6 Welsh RM, Che JW, Brehm MA et al. Heterologous immunity between viruses. Immunol Rev 2010; 235: 244–66. 7 Wedemeyer H, Mizukoshi E, Davis AR et al. Cross-reactivity between hepatitis C virus and influenza A virus determinant-specific cytotoxic T cells. J Virol 2001; 75: 11392–400. J Antimicrob Chemother 2012 doi:10.1093/jac/dks240 Advance Access publication 22 June 2012